Induced Changes in Ventilatory Responsiveness and Altitude Exposure
Status:
Terminated
Trial end date:
2013-02-28
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine if a drug (acetyl-cysteine or ACCY) can
increase the amount of oxygen in your body at a high altitude of 11,500 feet. ACCY is
approved by the Food and Drug Administration (FDA) as a treatment or antidote for Tylenol
overdoses. Other forms of ACCY are also sold over-the-counter as nutritional supplements. In
this study, the FDA-approved form of ACCY will be used "off-label" (meaning in a way not
approved by the FDA).
This study is being conducted by researchers from the United States Army Research Institute
of Environmental Medicine (USARIEM). The study will take place in the Altitude Chamber
located in the basement of USARIEM. A total of approximately 30 volunteers (men and women,
military and civilians) will take part in the study. They can expect to be in the study for a
minimum of a few hours each day for two weeks.
The investigators hypothesize that ACCY will improve ventilation and oxygenation while at
altitude.
Phase:
Phase 4
Details
Lead Sponsor:
United States Army Research Institute of Environmental Medicine